Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes

Here are the Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Types of regulatory t cells, regulatory transcription factors, how regulatory t cells work, follicular regulatory t cells, regulatory traffic signs, regulatory t cell expansion prevents blood, regulatory t cell expansion prevents retinal migraine, regulatory t cell expansion prevents retinal specialists, regulatory t cell expansion prevents retinal detachment, regulatory t cell expansion prevents initiative.

Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes

Background: The global incidence of type 2 diabetes (T2D) is rapidly increasing, with retinopathy being its most common complication and a leading cause of preventable blindness. Although the precise mechanisms involved in the development of diabetic retinopathy (DR) are not fully understood, defective immunomodulation is a recognized key factor in its pathophysiology. Regulatory T cells (Treg) regulate inflammation and promote regeneration, and while they are known to have important anti-inflammatory and neuroprotective roles in other tissues, including central nervous system, their role in the diabetic retina remains largely unknown. The aim of the present study is to examine the effect of Treg expansion of retinal neurodegeneration, an early event in the pathogenesis of DR.

Methods: Treg expansion was achieved by co-injecting recombinant mouse IL-2 with anti-IL-2 monoclonal antibody or its isotype in db/db mice as an establis hed model of T2D. Treg expansion was confirmed via flow cytometry in blood, spleen, and retina. Fundus angiography was performed in the days prior to animal sacrifice at 18 weeks. To study the effect of Tregs on retinal neurons, glia and vascular permeability, immunohistochemistry against Cone-Arrestin, PKCα, synaptophysin, ChAT, TH, GFAP, Iba-1, calbindin, Brn3a, RBPMS, isolectin B4, and albumin was used. Retinal VEGF levels were measured with a magnetic bead-based immunoassay, and NLRP3, Casp1, p20 and IL-18 were analyzed by Western Blot in retinal homogenates.

Results: There was a significant decrease in Treg in db/db mice blood. When this deficiency was corrected in db/db mice by systemic Treg expansion, there was an effective protection against retinal neurodegenerative, gliotic, inflammatory changes and vascular leakage associated with T2D. Importantly, Treg expansion did not impact the T2D phenotype in db/db mice as evaluated by blood glucose, HbA1c a nd circulating insulin.

Conclusion: Treg modulation in T2D offers a promising therapeutic approach to prevent early stages of DR. This strategy focuses on reducing neuroinflammation and mitigating the associated neuronal, glial, and vascular degenerative changes characteristic of DR. © The Author(s) 2024.

Authors : Llorián-Salvador M.; Pérez-Martínez D.; Tang M.; Duarri A.; García-Ramirez M.; Deàs-Just A.; Álvarez-Guaita A.; Ramos-Pérez L.; Bogdanov P.; Gomez-Sanchez J.A.; Stitt A.W.; Hernández C.; de la Fuente A.G.; Simó R.

Source : BioMed Central Ltd